Bausch Health Exits Medicaid, 340B: Future for Drugmakers?
- What: Bausch Health has ceased participation in Medicaid and the 340B drug discount program.
- Why it Matters: This move signals potential shifts in pharmaceutical company strategies regarding access programs and could impact drug pricing and patient access.
- What's Next: Industry analysts are watching to see if other drug manufacturers will follow suit, potentially leading to broader changes in drug access for vulnerable populations.
“`html
Bausch Health Exits Medicaid and 340B Program
Table of Contents
Updated October 28, 2025, at 17:03:15 PST
Background: Bausch Health and the Programs
On October 1, 2023, Bausch Health companies Inc. announced its withdrawal from both Medicaid and the 340B program. This decision impacts access to Bausch Health medications for a significant number of patients relying on these programs for affordability.
Medicaid is a joint federal and state program providing healthcare coverage to millions of Americans, including children, pregnant women, seniors, and individuals with disabilities. According to the Centers for Medicare & Medicaid Services (CMS), over 91 million Americans were enrolled in Medicaid and CHIP as of February 2024.
The 340B Drug Pricing Program, established in 1992, requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations – such as hospitals and clinics serving vulnerable populations – at substantially reduced prices. The Health Resources & Services Governance (HRSA) oversees the program, which aims to stretch scarce federal resources and improve access to care.
The Announcement and Lack of Explanation
Bausch Health disclosed its decision in a brief statement on its website, offering no specific rationale for the change. A company spokesperson stated that Bausch Health “remains fully committed” to patients and highlighted enhancements to its patient assistance program, including zero out-of-pocket costs and free home delivery for covered medications.
The lack of clarity surrounding the decision has raised concerns among patient advocacy groups and healthcare providers. Without a clear explanation, it’s difficult to assess the full impact of Bausch Health’s withdrawal.
Industry Context and Potential Motivations
Bausch Health’s move occurs amidst increasing pressure on the pharmaceutical industry to lower drug prices.The Trump administration, and afterward the Biden administration, have pursued various policies aimed at reducing prescription drug costs. These include proposals to tie Medicare drug prices to international reference prices and to address abuses within the 340B program.
Several factors may have contributed to Bausch Health’s decision:
- Price Pressure: The 340B program’s discounted prices can reduce revenue for manufacturers.
- Contract Negotiations: Negotiations with Pharmacy Benefit Managers (PBMs) and health plans can be complex and impact manufacturer profitability.
- Portfolio Management: Bausch Health has undergone significant restructuring in recent years, and this decision may be part of a broader strategy to streamline its business.
The company’s financial performance and debt load may also be playing a role. Bausch Health has faced financial challenges in the past, and maximizing revenue from all sources could be a priority.
potential Impact on Patients and Healthcare Providers
The withdrawal of Bausch Health from Medicaid and 340B could have several consequences:
- Increased Costs for Patients: Patients relying on Bausch Health medications through these programs may face higher out-of-pocket costs.
- Access Challenges: some patients may be unable to afford their medications, leading to treatment disruptions.
- Strain on Safety Net Providers: Hospitals and clinics serving vulnerable populations may experience increased financial strain if they are unable to access discounted drugs through 3